ORX750

DRUG4 trials

Sponsors

Centessa Pharmaceuticals UK Limited, Centessa Pharmaceuticals (UK) Limited

Conditions

Idiopathic HypersomniaNarcolepsy Type 1Narcolepsy Type 2Narcolepsy and Idiopathic Hypersomnia

Phase 2

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

RecruitingNCT06752668

Centessa Pharmaceuticals (UK) LimitedIdiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2

Start: 2024-12-23End: 2026-12-01Target: 248Updated: 2026-04-27

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects with Narcolepsy and Idiopathic Hypersomnia – (CRYSTAL-1)

RecruitingCTIS2024-518929-15-00

Centessa Pharmaceuticals UK LimitedNarcolepsy and Idiopathic Hypersomnia

Start: 2025-06-09Target: 34Updated: 2026-01-23

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

RecruitingNCT07096674

Centessa Pharmaceuticals (UK) LimitedIdiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2

Start: 2025-08-12End: 2026-04-30Target: 90Updated: 2026-04-16

A Phase 2, Long-term Extension Study of the Safety and Efficacy of ORX750 in Participants with Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored ORX750 Clinical Trial

Not yet recruitingCTIS2025-522987-34-00

Centessa Pharmaceuticals UK LimitedNarcolepsy and Idiopathic Hypersomnia

Target: 20Updated: 2026-02-12